Last year Discovery Park Technology Fund invested seed-funds in pioneering clinical development company, TC BioPharm (TCB) providing a launchpad for clinical trials of new treatments for cancer and viral infections.
In February 2016, the technology fund run by NCL Innovation, UK’s leading early stage technology investor, on behalf of Kent County Council announced its support of TC BioPharm (TCB), directly investing seed-finance of £500k from a fund focused on advanced immunotherapy research. Equity funds were subsequently increased by an additional £1m investment from NCL’s syndicate partners.
This Scotland-based technology company is focused on developing treatments for a variety of cancers and severe viral infections via an innovative immunotherapy process, where the body’s immune system is utilised to fight disease.
TCB’s lead product ImmunicCell® uses T lymphocytes (a type of white blood cell or killer cell) that have been grown in culture and specifically activated to target and kill cancerous tissue and infectious diseases.
DPTIF’s investment round in 2016 enabled TC Biopharm to initiate clinical trials, treating patients with various cancer types, including melanoma, lung and kidney cancer.
The investment was made by the Discovery Park Technology Investment Fund, run by KCC’s appointed fund manager NCL. It forms part of the £9m total raised by TC BioPharm over the last 12 months which has attracted a variety of private and institutional investors, including the Scottish Investment Bank and Japanese pharma company NIPRO.
Dr Mike Leek, Chief Executive of TCB, said: “We were delighted to have DPTIF funds ‘kick-start’ our clinical programme almost a year ago. NCL have been very supportive with the initial cornerstone investment made via the DPTIF.
“They continue to assist with our ongoing fundraising process. As the Company grows from strength to strength, we will continue working closely with NCL and the cluster of immunotherapy companies established at Discovery Park in Kent.”
Jerry Biggs, CEO of NCL Innovation, said: “We are delighted to be playing our part in the development of this exciting area of scientific research, working alongside KCC to give innovators the chance to fulfil their potential and continue to build Kent’s status as a centre of excellence for R&D.
“The Discovery Park Technology Investment Fund is proving to be a magnet for some of the most exciting technology companies working – like TCB on new treatments and processes that will revolutionise how science is conducted.”
Investors - Discovery Park Technology Investment Fund (DPTIF), Managed by NCL Innovation and supported by Kent County Council and the Regional Growth Fund.
About NCL Innovation (www.nareccapital.com/)
NCL Innovation (formally Narec Capital) – Is the UK’s Commercialisation Engine for novel technologies. NCL provides a seamless, integrated approach by deploying the relevant commercial, technical and financial skills that can surround an SME, with the talent required to guide and accelerate their concept through to commercial reality. NCL has offices both in London (Mayfair) and Discovery Park (Kent).
About TC Biopharm http://www.tcbiopharm.com/
TC BioPharm (TCB) is an immunotherapy company developing novel cell based products for treatment of cancer and severe viral infections. TCB employs a team of over 40 staff and acts as a fully integrated pharmaceutical company encompassing GMP Manufacture, quality, product development, regulatory affairs and in-house clinical research.
Search and find the perfect commercial property in Kent for your business. Locate in Kent gives advice and relocation support to international and UK companies looking to move or expand. Call +44 (0)1732 520700 or email firstname.lastname@example.org
IMAGERY USED WITHIN OUR SITE:
Locate in Kent would like to thank - Canterbury Christ Church University, Discovery Park, Frogmore, Kent County Council, Liberty Property Trust UK, London Array, Medway Council, Thanet Earth, University of Kent and Visit Kent - for the use of their images on this website.